ROXALL Medizin GmbH news
With a rising tendency and more than 150 million currently affected individuals in Europe the subject of allergy is more present than ever before.
This was reflected by the huge amount of international professional visitors of this year’s annual EAACI 2019 (congress of the European Academy of Allergy and Clinical immunology) taking place in Portugal’s capital and harbor city Lisbon.
ROXALL Medizin in Hamburg and the Portuguese Pharma group BIAL have signed a contract. ROXALL takes over the allergy-section that, till now, was known as BIAL-Aristeguí. With this acquisition ROXALL provides the base for further growth. The corporation in Bilbao is leading in the sector of specific immunotherapy and allergy investigation, one of their focuses being the investigation of recombinant allergens. Being close to important scientists is one advantage of the new producti